ALLMedicine™ Portal Hypertension Center
Research & Reviews 2,774 results
https://doi.org/10.1080/13543784.2022.2095259
Expert Opinion on Investigational Drugs; Rodrigues SG, Mendoza YP et. al.
Jun 28th, 2022 - Advanced chronic liver disease is considered a reversible condition after removal of the primary aetiological factor. This has led to a paradigm shift in which portal hypertension (PH) is a reversible complication of cirrhosis. The pharmacologic m...
https://doi.org/10.1111/jth.15797
Journal of Thrombosis and Haemostasis : JTH; Driever EG, Magaz M et. al.
Jun 25th, 2022 - A hypercoagulable state is not associated with development of portal vein thrombosis in cirrhosis, as we previously demonstrated. However, some groups demonstrated elevated levels of inflammatory markers and activation of haemostasis in the portal...
https://clinicaltrials.gov/ct2/show/NCT02417740
Jun 24th, 2022 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...
https://clinicaltrials.gov/ct2/show/NCT04365868
Jun 24th, 2022 - This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients with nonalcoholic s...
https://doi.org/10.1007/s10875-022-01299-1 10.1016/j.jaci.2013.12.1077 10.1007/s10875-019-00737-x 10.2147/CEG.S136803 10.14309/ajg.0000000000000140 10.1097/PAS.0b013e3180cab60c 10.15761/CCRR.1000149 10.1016/j.annpat.2013.10.019 10.3748/wjg.v18.i19.2430 10.3851/IMP1792 10.1007/BF02358376 10.1172/JCI105259 10.1086/606059 10.1007/s10875-010-9424-3 10.1016/0016-5085(81)90506-0 10.1016/S0022-3476(97)70200-2 10.1002/cyto.b.20432 10.1016/j.mad.2005.11.001 10.1111/cei.12002 10.1007/s11894-016-0491-3 10.1016/j.jpeds.2015.04.061 10.1007/s00246-001-0078-z 10.1172/JCI105656 10.1016/j.jpeds.2018.12.003 10.1007/s12185-017-2349-3 10.1186/s12969-016-0093-5 10.2500/aap.2015.36.3876 10.3748/wjg.14.1630 10.1157/13093278 10.1016/S1081-1206(10)61407-X 10.2169/internalmedicine.43.811 10.1136/heart.89.10.1130 10.1007/s004310000639 10.1007/s004310051220 10.1159/000201124 10.1007/BF01300099 10.1016/S0022-3476(75)80145-4 10.7326/0003-4819-68-2-398 10.1080/00365520802321220 10.1016/S0016-5085(97)70231-2 10.1136/jcp.s3-13.1.15 10.1016/j.diagmicrobio.2018.08.002 10.1111/pai.12734
Journal of Clinical Immunology; Sanges S, Germain N et. al.
Jun 24th, 2022 - As protein-losing enteropathy (PLE) can lead to hypogammaglobulinemia and lymphopenia, and since common variable immunodeficiency (CVID) is associated with digestive complications, we wondered if (1) PLE could occur during CVID and (2) specific fe...
Guidelines 7 results
https://doi.org/10.1016/j.clinre.2021.101767
Clinics and Research in Hepatology and Gastroenterology; Thabut D, Weil D et. al.
Aug 1st, 2021 - Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis/cirrhosis in asymptomatic patients at risk of developing clinically significant portal hypertension (CSPH, defined by a hepatic venous pressure gradient...
https://doi.org/10.1016/j.clinre.2021.101770
Clinics and Research in Hepatology and Gastroenterology; Corpechot C, Heurgue A et. al.
Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...
https://doi.org/10.1016/j.jacr.2021.02.013
Journal of the American College of Radiology : JACR; , Pinchot JW et. al.
May 8th, 2021 - Cirrhosis is a heterogeneous disease that cannot be studied as a single entity and is classified in two main prognostic stages: compensated and decompensated cirrhosis. Portal hypertension, characterized by a pathological increase of the portal pr...
https://doi.org/10.1016/j.cgh.2021.01.027
Clinical Gastroenterology and Hepatology : the Official C... Henry Z, Patel K et. al.
Jan 26th, 2021 - Management of bleeding gastric varices (GV) presents a unique challenge for patients with portal hypertension. Despite over thirty years of diagnostic and treatment advances standardized practices for bleeding GV are lacking and unsupported by ade...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306985
Gut Tripathi D, Stanley AJ et. al.
Mar 3rd, 2020 - These guidelines on transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of portal hypertension have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG...
Drugs 2 results see all →
Clinicaltrials.gov 389 results
https://clinicaltrials.gov/ct2/show/NCT02417740
Jun 24th, 2022 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...
https://clinicaltrials.gov/ct2/show/NCT04365868
Jun 24th, 2022 - This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients with nonalcoholic s...
https://clinicaltrials.gov/ct2/show/NCT00001971
Jun 24th, 2022 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...
https://clinicaltrials.gov/ct2/show/NCT02400216
Jun 24th, 2022 - Hepatitis C (HCV) is a leading cause of cirrhosis worldwide. Most complications associated with cirrhosis are driven by an altered portal circulation and the development of portal hypertension. Bacterial translocation (BT) from the gut to the syst...
https://clinicaltrials.gov/ct2/show/NCT05428267
Jun 23rd, 2022 - PREVALENCE OF ERECTILE DYSFUNCTION IN PATIENTS WITH CIRRHOSIS BEFORE AND AFTER LIVER TRANSPLANTATION. EFFECTIVENESS OF PHOSPHODIESTERASE-5 INHIBITORS. Research objectives The aims of investigators study are: (1) to compare the prevalence of erecti...
News 167 results
https://www.mdedge.com/internalmedicine/article/254814/hepatology/pi-based-daas-appear-safe-decompensated-patients
Jim Kling
May 22nd, 2022 - SAN DIEGO – An analysis of a large, international cohort suggests that treatment with protease-inhibitor (PI)–based direct-acting antivirals (DAAs) may be safe for patients with hepatitis C virus (HCV) with cirrhosis and early-stage liver decompen.
https://www.mdedge.com/gihepnews/article/254679/hepatocellular-carcinoma/tips-plus-sequential-systemic-therapy-shows
May 17th, 2022 - Key clinical point: Transjugular intrahepatic portosystemic shunt (TIPS) plus sequential systemic therapy is safe and feasible for treating portal vein tumor thrombus (PVTT)-related symptomatic portal hypertension (SPH) in advanced hepatocellular.
https://www.medscape.com/viewarticle/970596
Mar 21st, 2022 - Patients with cirrhosis and larger spontaneous shunt diameters showed a significantly greater increase in hepatic venous pressure gradient (HVPG) following balloon-occluded retrograde transvenous obliteration compared to patients with smaller shun...
https://www.mdedge.com/internalmedicine/article/252903/gastroenterology/shunt-diameter-predicts-liver-function-after
Heidi Splete
Mar 18th, 2022 - Patients with cirrhosis and larger spontaneous shunt diameters showed a significantly greater increase in hepatic venous pressure gradient (HVPG) following balloon-occluded retrograde transvenous obliteration compared to patients with smaller shun.
https://www.medscape.com/viewarticle/968905
Feb 22nd, 2022 - The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update highlighting the risk of serious liver injury following treatment with a combination therapy for cystic fibrosis. Ivacaftor/elexacaftor/tezacaftor (Kaft...
